Results 1 to 10 of about 447 (90)
Frontiers in Pharmacology, 2023 Soluble guanylate cyclase agonists and guanylate cyclase C agonists are two popular drugs for diseases of the cardiovascular system and digestive systems. The common denominator in these conditions is the potential therapeutic target of guanylate cyclase.
Qinan Yin +15 more
doaj +1 more source
Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC
Respiratory Research, 2022 Background Oxidative stress associated with severe cardiopulmonary diseases leads to impairment in the nitric oxide/soluble guanylate cyclase signaling pathway, shifting native soluble guanylate cyclase toward heme-free apo-soluble guanylate cyclase ...
Eva M. Becker-Pelster +18 more
doaj +1 more source
Current Modulation of Guanylate Cyclase Pathway Activity—Mechanism and Clinical Implications
Molecules, 2021 For years, guanylate cyclase seemed to be homogenic and tissue nonspecific enzyme; however, in the last few years, in light of preclinical and clinical trials, it became an interesting target for pharmacological intervention.
Grzegorz Grześk, Alicja Nowaczyk
doaj +1 more source
The soluble guanylate cyclase stimulator named vericiguat as an innovative heart failure therapy representative [PDF]
Farmacja Polska, 2021 A noticeable trend towards greater heart failure morbidity is observed in Poland as well as in the whole world. The percentage of people living with the above mentioned disease is growing mostly due to the process of ageing of populations.
Beata Jacuś +3 more
doaj +1 more source
Soluble guanylate cyclase α1-deficient mice: a novel murine model for primary open angle glaucoma. [PDF]
PLoS ONE, 2013 Primary open angle glaucoma (POAG) is a leading cause of blindness worldwide. The molecular signaling involved in the pathogenesis of POAG remains unknown.
Emmanuel S Buys +29 more
doaj +1 more source
Кардиоваскулярная терапия и профилактика, 2021 Heart failure is a severe disease with an unfavorable prognosis, which requires intensification of therapy and the search for novel approaches to treatment.
Zh. D. Kobalava, P. V. Lazarev
doaj +1 more source
Cytoglobin regulates NO-dependent cilia motility and organ laterality during development
Nature Communications, 2023 Cytoglobin is a heme protein with unresolved physiological function. Genetic deletion of zebrafish cytoglobin (cygb2) causes developmental defects in left-right cardiac determination, which in humans is associated with defects in ciliary function and low
Elizabeth R. Rochon +12 more
doaj +1 more source
Pulse, 2023 Introduction: A previous study of 200,000 exome-sequenced UK Biobank participants to test for association of rare coding variants with hypertension implicated two genes at exome-wide significance, DNMT3A and FES.
David Curtis
doaj +1 more source
Amyloid-β inhibits No-cGMP signaling in a CD36- and CD47-dependent manner. [PDF]
PLoS ONE, 2010 Amyloid-β interacts with two cell surface receptors, CD36 and CD47, through which the matricellular protein thrombospondin-1 inhibits soluble guanylate cyclase activation. Here we examine whether amyloid-β shares this inhibitory activity.
Thomas W Miller +4 more
doaj +1 more source
Portopulmonary hypertension practice patterns after liver transplantation
Liver Transplantation, EarlyView., 2022 Abstract Portopulmonary hypertension (POPH) is a type of pulmonary arterial hypertension occurring exclusively in those with portal hypertensive liver disease. Liver transplantation (LT) can significantly improve outcomes. Current guidelines counsel against immediate adjustments to targeted therapy after LT and suggest routine echocardiography as ...
Arun Jose +3 more
wiley +1 more source